Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-707 in metastatic colorectal cancer
NCT06493760Phase 2Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tivunatamig in metastatic colorectal cancer (mCRC), sponsored by 3S Guojian Pharmaceutical. Started Sep 2024; status: recruiting.
02
Drugs
tivunatamig
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06493760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493760.